enGene Therapeutics Inc. Public Float
enGene Therapeutics Inc. (ENGN) had Public Float of $154.18 million as of 2025-04-30, per its 10-K/A filed 2026-02-19.
Financial Statements › Notes › Cover Page
dei:EntityPublicFloat · last filed 2026-02-19
- 2025-04-30: Entity Public Float $154.18M.
- 2024-04-30: Entity Public Float $533.61M.
- 2024-01-25: Entity Public Float $43.85M.
| Period end | Entity Public Float |
|---|---|
| 2025-04-30 | $154.18M 10-K/A · filed 2026-02-19 |
| 2024-04-30 | $533.61M 10-K/A · filed 2025-02-20 |
| 2024-01-25 | $43.85M 10-K · filed 2024-01-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |